“LEQEMBI” (Lecanemab) for the Treatment of Alzheimer’s Disease Launched in South Korea
TOKYO and CAMBRIDGE, Mass., Nov 28, 2024 – (JCN Newswire via SeaPRwire.com) – Eisai Co., Ltd. and Biogen Inc. announced today that the humanized anti- soluble aggregated amyloid-beta (Aβ) monoclonal antibody “LEQEMBI®” has been launched in South Korea. LEQEMBI received the Ministry of Food and Drug Safety (MFDS) approval in May 2024 for treatment in […]












